Finance

Beta
Lists
HDP1:FRA
Arrowhead Pharmaceuticals Inc
€62.08
-1.30%
(-0.82) 1D
Jun 4, 8:10:03 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for HDP1...
Open
€62.08
High
€62.08
Low
€62.08
Mkt. cap
10.22B
Avg. vol.
10.00
Volume
0.00
52-wk high
€68.88
52-wk low
€12.50
No. of employees
711
Open
€62.08
High
€62.08
Low
€62.08
Mkt. cap
10.22B
Avg. vol.
10.00
Volume
0.00
52-wk high
€68.88
52-wk low
€12.50
No. of employees
711
News stories
From sources across the web
Profile
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. Wikipedia
About Arrowhead Pharmaceuticals Inc
CEOChristopher Richard Anzalone
Employees711
FoundedJan 1, 2004
HeadquartersPasadena, California, United States
SectorBiotechnology
Websitearrowheadpharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
27.77M
256.47M
264.03M
73.74M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
155.91M
181.07M
173.52M
165.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.41M
31.29M
49.70M
49.34M
Operating expense
193.32M
212.37M
223.22M
215.00M
Total operating expenses
193.32M
212.37M
223.22M
215.00M
Operating income
-165.55M
44.11M
40.81M
-141.26M
Other non operating income
-176.00K
4.66M
277.00K
-1.61M
EBT including unusual items
-179.09M
36.12M
28.27M
-137.56M
EBT excluding unusual items
-179.09M
36.12M
28.27M
-156.56M
Income tax expense
-437.00K
20.00M
29.00K
7.00K
Effective tax rate
0.24%
55.37%
0.10%
-0.01%
Other operating expenses
-
-
-
-
Net income
-175.24M
-23.75M
30.81M
-132.73M
Net profit margin
-631.11%
-9.26%
11.67%
-180.01%
Earnings per share
-1.26
-0.18
0.22
-0.93
Interest and investment income
11.02M
9.05M
9.69M
16.87M
Interest expense
-24.38M
-21.69M
-22.50M
-23.85M
Net interest expenses
-13.36M
-12.64M
-12.82M
-6.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-159.33M
50.49M
47.20M
-134.89M
Gain or loss from assets sale
-
-
-
-19.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer